Zacks Research Cuts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research dropped their Q4 2025 EPS estimates for shares of Gilead Sciences in a note issued to investors on Thursday, November 13th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $1.81 per share for the quarter, down from their prior forecast of $1.82. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q1 2026 earnings at $1.69 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $2.32 EPS, Q4 2026 earnings at $2.31 EPS, FY2026 earnings at $8.13 EPS, Q1 2027 earnings at $1.97 EPS, Q2 2027 earnings at $2.14 EPS, Q3 2027 earnings at $2.55 EPS and FY2027 earnings at $9.04 EPS.

A number of other research analysts have also recently issued reports on GILD. Wolfe Research lifted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Wells Fargo & Company lifted their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $129.13.

Gilead Sciences Stock Down 1.5%

Shares of NASDAQ GILD traded down $1.94 on Friday, reaching $123.26. 1,871,631 shares of the company’s stock traded hands, compared to its average volume of 7,940,996. The business’s 50 day simple moving average is $117.24 and its two-hundred day simple moving average is $112.64. Gilead Sciences has a 12 month low of $86.08 and a 12 month high of $127.68. The company has a market cap of $152.93 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 94,646 shares of company stock valued at $11,311,286 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Activest Wealth Management boosted its holdings in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC raised its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the second quarter worth about $27,000. Finally, Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.